Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab and Anlotinib in Neoadjuvant NSCLC
NCT05387109Phase 4Unknown
- Sponsor
- Tangdu Hospital
- Start
- Jun 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
Phase 4, open-label, single-arm trial of penpulimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response at 12 months. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05387109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387109.